Polynucleotide Kinase/Phosphatase (PNKP) is a key enzyme in DNA repair, helping cancer cells resist treatments like radiation and chemotherapy. By targeting PNKP, researchers aim to make prostate cancer cells more vulnerable to therapy-induced DNA damage.
This approach is especially promising for tumors with mutations in DNA repair genes like ATM and BRCA, which are often found in advanced prostate cancer.
A new PNKP inhibitor is set to enter Phase 1 clinical trials in 2025, offering hope for more effective treatments by overcoming resistance mechanisms and enhancing existing therapies.
I could not find an official name of the drug, but I think it's A83B4C63...
Docosahexaenoic acid enhances the treatment efficacy for CRPCa by inhibiting autophagy through Atg4B inhibition, 2024 Aug 23